AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
SAN DIEGO, April 05, 2016 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that Charles Theuer, M.D, Ph.D., President and CEO, will present at the 15th Annual Needham Healthcare Conference at 10:40 am EDT on Tuesday, April 12, 2016, at the Westin Grand Central Hotel in New York, NY.
To access a live webcast of the presentation, please visit the “Events and Presentation” section within the “Investors” section of the TRACON Pharmaceuticals website at www.traconpharma.com. A replay of the webcast will be available on the website for 60 days following the event.
About TRACON
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes two product candidates: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers and wet AMD through a collaboration with Santen Pharmaceutical Company Ltd., and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact: Casey Logan Chief Business Officer (858) 550‐0780 ext. 236 [email protected] Investor Contact: Andrew McDonald LifeSci Advisors LLC 646-597-6987 [email protected]
